Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 63

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 63
---
 all our rights, assets, liabilities and obligations, except that our affairs
ceased to be governed by the Delaware General Corporation Law, the Certificate of Incorporation, as amended, and became subject to the
Nevada Revised Statutes, Articles of Incorporation and our new bylaws subject to the Nevada Revised Statutes. The Reincorporation did
not change the number of the authorized shares of the Company, its par value, or its issued and outstanding shares. Additionally, on
March 3, 2025, the corporate name of Revium Recovery Ltd., our subsidiary, was changed to “Revium RX Ltd.”

On July 23, 2024, we consummated the Share Exchange
contemplated by the Stock Exchange Agreement, dated November 14, 2023 (the “Share Exchange Agreement”), by and among the
Company, LipoVation Ltd., a company organized under the laws of the State of Israel (“LipoVation”), and all shareholders
of LipoVation (the “LipoVation Shareholders”). As a result of the consummation of the Share Exchange, LipoVation became a
wholly owned subsidiary of the Company. At such date, the shareholders of LipoVation contributed all of their shareholdings in LipoVation
in exchange for 23,171,642 shares of the Company’s Common Stock (the “Exchange Shares”), with each LipoVation Shareholder
receiving a pro rata portion of the Exchange Shares based on their ownership in LipoVation, in consideration of their contribution to
the Company of all of the outstanding capital stock of LipoVation. Following the closing, 40% of the issued and outstanding shares of
the Company’s Common Stock immediately upon the closing of the Share Exchange were held by the former LipoVation shareholders.

As a result of the Share Exchange, the Company
acquired the business of LipoVation, which became the primary business of the Company. Through LipoVation, the Company is committed to
developing innovative nano-therapeutics and anti-infectives to deliver advanced treatment solutions for diseases with limited or no effective
treatment options

Also, after the closing of the Share Exchange,
the Company discontinued all its efforts to develop its novel clinical Decision Making Support Systems (DMSS).

<div align='center'>36</div>

Private Placement Offerings

Between December 2020 and August 2022, the Company
con